Detalhe da pesquisa
1.
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Cell
; 161(2): 319-32, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25843629
2.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(10): 1353-1364, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871584
3.
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Blood
; 133(1): 70-80, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30322870
4.
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
Blood
; 134(26): 2369-2382, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697821
5.
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.
Blood
; 132(8): 825-836, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880615
6.
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Haematologica
; 105(5): 1361-1368, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471373
7.
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Blood
; 129(23): 3071-3073, 2017 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356247
8.
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Proc Natl Acad Sci U S A
; 113(21): 5999-6004, 2016 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27162338
9.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med
; 372(4): 311-9, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482239
10.
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Blood
; 127(18): 2203-13, 2016 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26773040
11.
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Blood
; 127(7): 869-81, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26702065
12.
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Nature
; 481(7379): 90-3, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113614
13.
Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma.
Blood
; 123(14): 2189-98, 2014 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24563408
14.
MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Biochim Biophys Acta
; 1846(2): 457-67, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25199984
15.
Resolving the daratumumab interference with blood compatibility testing.
Transfusion
; 55(6 Pt 2): 1545-54, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25764134
16.
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Proc Natl Acad Sci U S A
; 109(10): 3879-84, 2012 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343534
17.
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.
Proc Natl Acad Sci U S A
; 108(37): 15336-41, 2011 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21873242
18.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Nat Med
; 30(1): 240-248, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071379
19.
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Br J Haematol
; 161(2): 204-13, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23432194
20.
Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.
Oncology
; 84(6): 362-70, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23689165